12:00 AM
 | 
Aug 01, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Trans sodium crocetinate regulatory update

FDA granted Orphan Drug designation for Diffusion's trans sodium crocetinate (TSC) to treat glioblastoma multiforme (GBM). Diffusion plans...

Read the full 66 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >